Alzheimer disease (AD) is a devastating neurodegenerative disorder first recognized in 1907 by Alois Alzheimer (1) . Though initially described in a 51-year-old woman, AD is now recognized as a common disease in the elderly and is the predominant cause of dementia in people over 65 years of age. Clinical symptoms typically begin with subtle short-term memory problems. As the disease progresses, difficulty with memory, language, and orientation worsen to the point of interfering with the ability of the person to function independently. Though the pattern and rate of cognitive loss varies, a common feature of the disease is continuous progression until virtually all cognitive function is lost. Duration of AD from first symptoms of memory loss until death is, on average, 10 years but can span from 5 years to more than 20 years. Death occurs from secondary causes such as aspiration pneumonia.
The pathology in AD is confined to the central nervous system. The predominant features are amyloid deposits and neurofibrillary tangles (NFTs). Amyloid is associated with the vascular system of the central nervous system and is found as focal deposits in the parenchyma. The major component in this amyloid is a highly hydrophobic peptide called the AP3 peptide, which ranges in length from 39 to 43 amino acids. This peptide was first partially sequenced in 1984 (2) in material purified from vascular amyloid deposits. Subsequent work showed that plaque amyloid contained the same peptide, but with an extended C terminus (3) . The AP3 peptide aggregates into antiparallel filaments in a (3-pleated sheet structure that results in the birefringent nature of amy-. loid in the presence of Congo red and polarized light. Surrounding many plaques are dystrophic neurites, which are nerve endings containing abnormal filamentous and membranous structures. Activated astrocytes and microglial cells also surround plaques. NFTs consist of abnormal paired helical filaments bundled together in neuronal cell bodies. "Ghost" NFTs are also observed that presumably mark the location of dead neurons. Other features include granulovacuolar changes, Hirano bodies, neuronal loss, gliosis, and the variable presence of Lewy bodies.
In the AD brain, the destructive process is evident on a gross level. Late in the disease, ventricular enlargement and shrinkage of the brain occurs, but with sparing of the motor strip. Microscopically, extensive gliosis and neuronal loss are observed. Thus, the pathology seen at autopsy is the end-point of a lengthy disease process, far removed from the initiating events of AD. Also, the types of cells remaining at death are different from those of a normal brain, with neurons missing that were possibly involved in initiating events. Other cell types such as the activated microglial cells and astrocytes have gene expression patterns not observed in the normal brain (4) . Thus, attempts using biochemical methods to identify key proteins and genes involved in disease initiation are hampered by the fact that it is not possible to actually observe these critical in vivo events. Rather, biochemical dissection of the AD brain at autopsy is akin to molecular archaeology, attempting to reconstruct the pathogenic pathway studying the end-stage disease brain. Genetic mapping and positional cloning approaches to identifying AD genes are attractive because these methods do not rely on a comprehensive understanding of pathogenesis but, rather, require 8552 accurate diagnosis of the disease in familial forms of AD. When genes harboring AD mutations are identified, the protein products of these genes must be critical to initiating events of pathogenesis.
The Amyloid Precursor Protein Gene (APP) and Familial AD (FAD)
The APP Gene. The first genetic defects leading to AD were identified in the APP gene. Sequences encoding APP were first cloned (5) by screening cDNA libraries with oligonucleotide probes deduced from the AP3 peptide sequence. The initial fulllength cDNA clone identified encoded a 695-amino acid protein (APP695) that contained, near its C-terminal end, the Af3 peptide sequence (Fig. 1) . Subsequent work showed that the APP gene has 19 exons (6) and that the A,B peptide is encoded by parts of exons 16 and 17 (6) (exon and codon numbering based on the APP770 splice variant). A number of APP transcripts have been described in which (exons 7, 8, and 15 are alternatively spliced. Exon 7 encodes 57 amino acids with homology to the Kunitz-type protease inhibitor (KPI) domain (7) (8) (9) , and exon 8 encodes 19 amino acids with homology to the MRC OX-2 antigen (9) . In neurons, the predominant transcript is APP695 (10) referred to as L-APPs (11, 12) . While all of the above-mentioned splice variants contain AP3 sequences, two additional rare transcripts, APP365 and APP563, have been identified that lack A,B-encoding sequences (13, 14) . Other genes have been identified that are homologous to APP (15) (16) (17) 31 and Fig. 1 ). This mutation has subsequently been identified in a number of FAD families of different ethnic origins (32-36) but not in a large number of controls, most other early-onset kindreds, and both FAD and "sporadic" late-onset AD patients (29, 31, 37, 38) . (The term sporadic is used here to indicate AD subjects with no family history of AD and does not necessarily imply a nongenetic etiology.) Subsequently, two other point mutations at codon 717 were identified, each in a single family (39, 40) . One results in Phe-717 (39) , and the other results in Gly-717 (40) . A double mutation has been identified in a Swedish pedigree at codons 670 and 671 resulting in Asn-Leu in place of the normal Lys-Met (41). These mutations are in exon 16 of the APP gene and encode the 2 amino acids immediately preceding the beginning of the A,B sequence. Another pathogenic APP mutation has been identified in a Dutch family with both cerebral hemorrhage disease and presenile dementia (42) . This mutation, also in the A,3 region, is at codon 692 and results in a Gly -> Ala replacement.
The disease in this family is a variant of both HCHWA-D disease and AD. Exhaustive screening of other early-onset AD, late-onset FAD, and sporadic AD patients and a large number of controls has been performed for each of these mutations (29, 37, 38, 43) , and all are only rarely observed in dementia pedigrees and have never been seen in controls. Thus, these are clearly pathogenic causative mutations.
The clinical, neuropathologic, and genetic characteristics of AD observed in subjects with APP mutations have several features in common. (i) Onset of AD is early. In Ile-717 subjects, the age of onset ranges from 41 to 64 years, with family age-of-onset means ranging from 48 to 55 years (32, 34, 44, 45) . For the Gly-717 kindred, the onset mean is 59 years (range, 40-67 years) (40, 46) . In the Phe-717 family, the onset mean is 43 years (range, 39-51 years) (47) . For the Asn-670/Leu-671 mutation, the family onset mean is 55 years (range, 45-61 years) (48) . (ii) Inheritance is dominant with complete penetrance by the early 60s; noAPP mutation carrier past the age of 67 years has been reported. (iii) Other than the age of onset, the clinical and neuropathologic features of AD in these families are not different from AD in non-APP mutation subjects.
APP Mutations and AD Pathogenesis. The location of the pathogenic APP mutations is intriguing because all are located within or flanking the Af3 peptide region of the amyloid precursor protein P3PP and hence may affect proteolytic processing of the protein (Fig. 1 (57, 58) . The longer peptides form amyloid fibrils more rapidly than A,3-(1-40) and thus are postulated to be more pathogenic (59) (60) (61) . The Gly-692 mutation, which lies within the A,B sequence, also appears to alter O3PP processing; A,B production was increased by a factor of 2 (62) . Identifica (65, 71, 72) .
When the AD3 locus was initially identified, the flanking markers were D14S52 and D14S53 with the disease gene interval being 23 centimorgans (Fig. 2) . The AD3 region has now been refined to between D14S61 and D14S289 (66), which spans -8 centimorgans. Initial candidate genes in the region included FOS and HSP70 (63) . Mutational analysis of the FOS gene (73, 74) failed to detect mutations. Cloning and mapping of the HSPA2 gene eliminated it as a candidate (75) . Subsequent to the initial localization ofAD3, the genes for transforming growth factor /3 (76) and dihydrolipoyl succinyltransferase (77) have been mapped to this region and are currently being evaluated for AD3 mutations.
AD3 and a Second Chromosome 21 Locus. Identification of the chromosome 14 locus permitted reevaluation of the hypothesis that there is an FAD gene on chromosome 21, distinct from the APP locus (19, 21, 22, 78 (88) . The clinical features characteristic of AD in these families include prominent seizures, myoclonus, and paratonia, which have been observed in many of the sub- jects from different families (81, 83, 87, 88) . These features are more variable, occurring later in the course of the disease in other forms of AD (89, 90) . The exception in the AD3 kindreds may be the SNW/FAD3 family (88) , in which extrapyramidal signs, seizures, and myoclonus were not observed (82) . This family, as well as FAD1 (87), may be examples of allelic heterogeneity compared to other AD3 kindreds in that both have a later age of onset compared to other AD3 families, and the duration of disease is somewhat longer with some individuals living up to 18 years after onset of symptoms. Neuropathologic studies of the AD3 families have shown extensive senile plaques, NFTs, and granulovacuolar changes in the hippocampus. Amyloid deposits in the cerebellum were a more variable feature and were not observed in all patients autopsied (83, (88) (89) (90) . In summary, the clinical and neuropathologic phenotype of AD3 families overlaps those observed in other forms of AD. Inheritance is autosomal dominant, with penetrance complete by the age 50 in many families and by the late 50s in others ( Table 1 ). The AD3 locus accounts for about 90% of earlyonset autosomal dominant AD.
The VG Kindreds
The APP and AD3 loci do not explain all early-onset FAD. Evidence for an additional early-onset locus comes from studies of the VG kindreds. These families come from a group of Germans who, in the 1760s, emigrated to the Volga river region of Russia (80, 91 Linkage analysis of the VG families with chromosome 21 markers has yielded negative results (23, 24, 29) and no mutations have been identified in theAPP gene (29) . Similarly, linkage analysis with chromosome 14 markers nearAD3 (63, 71) and with the chromosome 19 APOCII STRP locus gave negative results (68, 92) . Thus, the locus responsible for AD in the VG kindreds remains to be mapped. Other early-onset families have been reported in which the APP gene and the chromosome 14 locus has been excluded (72, 93) .
Apolipoprotein E (apoE) and Late-Onset AD Genetic dissection of late-onset AD is problematic for the following reasons. First, the disease is common in the elderly with prevalence estimates reaching as high as 18 .7% (94) (95) . Positive genetic association results had also been reported for an allele of a restriction fragment length polymorphism locus at APOCII (68, 96) .
Definitive identification of the chromosome 19 AD locus was achieved by screening for proteins that could bind to immobilized AP. Strittmatter et al. (97) found that an AO3 binding factor in cerebral spinal fluid was apoE. In the same study, the relevance of APOE to late-onset AD was examined by genotyping patients from late-onset FAD kindreds for the APOE E2/£3/£4 polymorphic system. This polymorphism consists of single-base changes at codons 112 and 158, which encode Cys-112 and Cys-158 for the s2 allele, Cys-112 and Arg-158 for the £3 allele, and Arg-112 and Arg-158 for the E4 allele, with respective allele frequencies of 0.08, 0.78, and 0.14 in Caucasian controls. A strong allelic association between AD and the s4 allele of APOE was reported by using late-onset FAD families; the frequency of e4 in AD patients being 0.52 compared to 0.14-0.16 in controls (97) .
The APOE e4 association with AD was rapidly confirmed in numerous studies of late-onset AD (102) . Since these initial confirmatory reports have appeared, numerous other reports of elevated £4 alleles have been published. The association has also been observed in a number of different ethnic groups including Japanese (100, 108-110), African Americans (111, 112) , and Hispanics (112) . The fact that the allelic association is observed in different ethnic groups indicates that the observed relationship between the £4 allele and AD is not an artifact of population stratification. While most of the populations studied have been late-onset, one report of an early-onset population-based group (onset < 65 years; sample mean = 57 years) has also shown an allelic association of AD with s4 (113) . However, in another study of Japanese early-onset sporadic AD cases (mean age of onset = 52.8 years), no allelic association was observed (s4 frequency = 0.08 in AD patients vs. 0.095 in controls) (110) .
E4 Allele Dose Effects. The s4 allele appears to act as a dose-dependent ageof-onset modifier (114) . The highest risk is associated with the s4/s4 genotype, with significant but intermediate risk associated with the s3/s4 genotype. Corder et al. (114) reported that in a late-onset FAD group, each copy of the e4 allele reduces the age of onset by 7-9 years, with onset mean ages of 84.3 years, 75.5 years, and 68.4 years reported for no E4, one £4 allele, and two £4 alleles, respectively. A dose-dependent age-of-onset effect has also been observed in other FAD groups (115, 116) , and in late-onset sporadic subjects (117) , including those from a population-based study (106) .
The Protective Effects of the APOE E2 Allele. While the e4 frequency appears to be elevated in AD cases, in some studies, the E2 allele frequency in AD patients is lower than controls, leading to the suggestion that s2 may be protective against AD (118) . This reduced s2 frequency has been observed in numerous AD APOE studies, although the difference has not always been statistically significant (92, 97, 98, 102, 106, 110 (119) . In a different family with the Ile-717 mutation and a mean age of onset at 47.6 ± 3.0 years, the affected subjects (n = 3) are E3/E4, while one mutation carrier, who is s2/E3, remains unaffected at an age 2 standard deviations past the onset mean for the family (120) . These data are consistent with APOE genotypes modifying the age of onset inAPP mutation families, although more subjects need to be analyzed to validate this hypothesis. However, in a much larger study of HCHWA-D and the Gln-693 mutation, in which 31 affected subjects were genotyped for APOE and extensively clinically and neuropathologically characterized, no interaction between APOE genotypes and disease expression was observed (121, 122) . Likewise, APOE genotypes do not influence expression of the chromosome 14 AD3 locus (123, 124) .
Linkage Disequilibrium and APOE. The genetic evidence for a strong allelic association between APOE and AD indicates that either the s4 form of apoE is the gene product involved in AD pathogenesis or that the actual disease gene is a closely linked locus in linkage disequilibrium with APOE. The finding that E4 increases risk for AD and that s2 is protective in many Caucasian populations supports but does not prove the hypothesis thatAPOE is the pathogenic locus. The reported exception to this risk pattern is in an AfricanAmerican AD population in which both 64- (128) . In vitro experiments demonstrate that apoE binds to AP3 in an isoform-specific fashion (129) , with apoE-s4 binding more rapidly to A,3 compared to apoE-e3. However, in another study, Apo-E3 bound better than ApoE-s4 (130) . Ma et al. (131) , who used amyloid fibril formation evaluated by electron microscopy as a measure of ApoE-Af interaction, noted that apoE-s4 promoted fibril formation better than apoE-s3. Evans et al. (132) reported that apoE inhibited an initial nucleation step in fibril formation but did not affect subsequent growth of fibrils. The disulfide form of apoE-e3 was a more potent nucleation inhibitor than apoE-e4. Thus, while it is clear that apoE can bind to A,B in vitro, whether an apoE-A,B interaction occurs in vivo and whether these interactions are relevant to AD are not presently known.
Another hypothesis is that apoE influences formation of NFTs by binding to tau protein, the major component of these structures (133) . apoE isoform-dependent binding to tau has been reported with apoE-e3 binding more tightly than apoE-£4. Formation of the apoE-tau complex possibly prevents tau from being phosphorylated and from forming NFTs. Again, the relevance of apoE-tau interactions to AD pathogenesis has not been demonstrated in vivo.
The role of apoE in AD pathogenesis could involve apoE acting as a neuronal injury response protein (for a recent review, see ref. 134 ). ApoE production is elevated several hundredfold in a sciatic nerve injury model (135) (136) (137) . The presumed role of apoE in repair is as a lipid transport protein that mobilizes cholesterol after injury. During regeneration, apoE particles are taken up via the low density protein receptor (138) as a source of cholesterol for membrane synthesis and remyelination. In the central nervous system, apoE levels are also elevated to a lesser extent in an entorhinal cortex lesion model (139) . Also, apoE appears to promote neuronal extension by an isoformdependent mechanism. In experiments with cultures of dorsal root ganglion neurons in the presence of /3 very low density lipoprotein, apoE-e3 promoted neurite outgrowth whereas apoE-e4 inhibited both outgrowth and branching (140) . Thus, the risk for AD associated with the s4 allele could be the result of apoE's role as a lipid transport protein for synaptogenesis after injury.
Conclusions
The work summarized above shows that AD is genetically heterogeneous. For early-onset autosomal dominant AD, in addition to the APP gene and the chromosome 14 locus AD3, at least one other locus remains to be mapped. For lateonset AD, the work on APOE shows that the £4 allele is a risk factor for developing AD. However, 50-60% of all AD patients do not have an e4 allele. Other loci contributing to late-onset AD remain to be detected and mapped. As in other common complex diseases, these additional loci may involve gene-gene interactions, perhaps involvingAPOE. Identification of all susceptibility loci for AD is a major goal in resolving the pathogenesis of AD. However, gene identification is only an intermediate step in solving AD or any genetic disorder. Substantial additional effort will be needed to understand how each susceptibility factor is involved in AD pathogenesis.
Note Added in Proof. After this manuscript was prepared, the AD3 gene was cloned (141 (142) .
In another recent development, the locus responsible for AD in the VG kindreds was mapped by linkage analysis (143) . Markers spanning the genome were tested for linkage and positive results were obtained for markers on chromosome 1q31-42. For one marker, D1S479, in five of seven VG families tested, a common allele cosegregating with the disease was identified. Subsequent work identified a homologue of the S182 chromosome 14 gene (144) that is 67% identical to S182. The homologue was mapped to chromosome 1 and to a yeast artificial chromosome that also contained DlS479. DNA sequence analysis identified a candidate pathogenic mutation at codon 141 that resulted in the substitution of an isoleucine for the wild-type asparagine. The mutation occurs at an amino acid conserved in the S182 gene and the S182 mouse homologue. The 
